The role of the Wnt signaling pathway in incretin hormone production and function by Yu-ting A. Chiang et al.
REVIEW ARTICLE
published: 12 July 2012
doi: 10.3389/fphys.2012.00273
The role of the Wnt signaling pathway in incretin hormone
production and function
Yu-ting A. Chiang1,2, Wilfred Ip2,3 and Tianru Jin1,2,3*
1 Department of Physiology, University of Toronto, Toronto, ON, Canada
2 Toronto General Research Institute, University Health Network, Toronto, ON, Canada





Xiaolong Liu, Institute of
Biochemistry and Cell Biology, China
Yusuf Ali, Agency for Science,
Technology and Research, Singapore
*Correspondence:
Tianru Jin, Department of
Physiology, University of Toronto,
Rm. 10-354, Toronto Medical
Discovery Tower, 101 College Street,
Toronto, ON, M5G 1L7, Canada.
e-mail: tianru.jin@utoronto.ca
Glucose metabolism is tightly controlled by multiple hormones and neurotransmitters
in response to nutritional, environmental, and emotional changes. In addition to insulin
and glucagon produced by pancreatic islets, two incretin hormones, namely glucagon-like
peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP, also known as glucose-dependent
insulinotropic peptide), also play important roles in blood glucose homeostasis. The
incretin hormones mainly exert their regulatory effects via their corresponding receptors,
which are expressed in pancreatic islets as well as many other extra-pancreatic organs.
Recent studies have shown that the genes which encode these two incretin hormones
can be regulated by the effectors of the Wnt signaling pathway, including TCF7L2, a
transcription factor identified recently by extensive genome wide association studies as an
important type 2 diabetes risk gene. Interestingly, TCF7L2 and β-catenin (β-cat), another
effector of Wnt signaling pathway, may also mediate the function of the incretin hormones
as well as the expression of their receptors in pancreatic β-cells. In this review, we have
introduced the incretin hormones and the Wnt signaling pathway, summarized recent
findings in the field, and provided our perspectives.
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INTRODUCTION
The metabolic syndrome is a multifactorial disease involving
complex interactions between aging, genetics, behavior, and envi-
ronment. Several peptides, hormones, and neurotransmitters
are involved in maintaining glucose and energy homeostasis in
response to nutritional, environmental, and emotional changes.
In response to fasting and feeding, pancreatic islet α-cells and
β-cells secrete glucagon and insulin, respectively, to maintain
blood glucose homeostasis. In the beginning of the 19th century,
scientists observed that oral glucose administration generates a
much stronger insulin secretory response from pancreatic β-cells
compared to intravenous injection of equal amounts of glu-
cose (Bayliss and Starling, 1902). Hence, incretins are defined
as a group of gastrointestinal hormones that potentiate insulin
release from pancreatic islet α-cells after food ingestion, prior to
the elevation of blood glucose levels. The first incretin, gastric
inhibitory polypeptide (GIP, also known as glucose-dependent
insulinotropic peptide) was discovered by Brown and colleagues
in the 1970’s (Brown, 1971; Brown and Dryburgh, 1971; Dupre
et al., 1973; Brown et al., 1975; Ross et al., 1977). About a decade
later, the cDNA encoding glucagon in fish, rodents, and humans
was isolated which lead to the discovery of the second incretin,
glucagon-like peptide-1 (GLP-1) (Bell et al., 1983a,b; Philippe
et al., 1986).
GLP-1 is encoded by the proglucagon gene (gcg) and is pro-
duced in intestinal L cells. The same gcg is also expressed in
pancreatic α-cells, where it encodes the key glucose-elevating hor-
mone glucagon. As intestinal GLP-1 and pancreatic glucagon are
encoded by the same gcg gene but exert opposite effects on glucose
homeostasis, great efforts have been made to decipher signaling
pathways that regulate gcg expression in a tissue-specific man-
ner (Lu et al., 1996; Jin et al., 1997; Ni et al., 2003; Jin, 2008).
Our group has demonstrated that the two key effectors of the
Wnt signaling pathway, β-catenin (β-cat) and TCF7L2, specifi-
cally up-regulate gcg mRNA expression and GLP-1 production
in gut endocrine L cells (Ni et al., 2003; Yi et al., 2005). Shortly
after we presented this finding (Ni et al., 2003; Yi et al., 2005),
TCF7L2 was identified as an important type 2 diabetes (T2D)
risk gene in a large-scale genome-wide association study (GWAS)
(Grant et al., 2006). Specifically, two single nucleotide polymor-
phisms (SNPs) within the intronic regions of TCF7L2 are robustly
associated with the risk of T2D. This important finding has been
confirmed in numerous studies involving different ethnic groups
during the past five years (Grant et al., 2010). Interestingly, it
was demonstrated that the Wnt signaling pathway and the TCF
effector also regulate the expression of gip (Garcia-Martinez et al.,
2009). Furthermore, recent investigations revealed that the effec-
tors of the Wnt signaling pathway may modulate the functions
of the two incretin hormones as well, and that TCF7L2 regulates
the expression of the GLP-1 receptor (GLP-1R) and GIP receptor
(GIPR) in pancreatic β-cells (Liu and Habener, 2008; Shu et al.,
2009). Finally, the Wnt effectors β-cat and TCF7L2 have been
shown to play potential metabolic roles in organs other than the
pancreas and gut. In this article, we first provide a brief overview
of the incretin hormones and theWnt signaling pathway.We then
summarize recent findings on the role ofWnt signaling in incretin
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hormone production and function. This is followed by the pre-
sentation of our views and perspectives. Mechanistic exploration
of the function of the two incretin hormones has been sum-
marized in numerous recent reviews elsewhere (Brubaker and
Drucker, 2004; Hansotia and Drucker, 2005; Baggio and Drucker,
2007; Ussher and Drucker, 2012).
INCRETIN HORMONES
In 1902, two English physiologists, Sir William Maddock Bayliss
and Ernest Henry Starling speculated that intestinal mucosa con-
tains a hormone which stimulates endocrine secretions from
the pancreas after the ingestion of carbohydrates (Bayliss and
Starling, 1902). They coined the term “secretin” for the yet to be
identified hormone, which even preceded the discovery of insulin
in 1921 by the team consisting of Frederick Banting, Charles
Best, John Macleod, and James Collip. In the 1930s, the terms
“incretin” or “enterogastrone” were proposed by several scientists
for a hormonal extract from the duodenum (Cho and Kieffer,
2010). Since the glucose lowering effect was not reproducibly
appreciable and experimental methods to reliablymeasure insulin
secretion were lacking at that time, research in this field was not
actively pursued until nearly half a century later.
The new era of incretin research started in the 1970’s with
the recognition of the glucose-lowering effect of GIP (Dupre
et al., 1973; Brown et al., 1975; Ross et al., 1977), followed by
the identification of GLP-1 in the mid-1980’s (Bell et al., 1983b;
Scott et al., 1983). The majority of GIP is produced by intestinal
endocrine K cells in the mucosa of the duodenum and jejunum;
however, the gip gene has also been shown to be expressed in
the pancreatic α-cells (Fujita et al., 2010). As shown in Figure 1,
GIP is encoded by the gip gene and is derived from a 153
amino acid pro-hormone, proGIP. In the gut, post-translational
processing by the prohormone convertase PC1/3 (PC3) leads
to the production of the biologically active hormone GIP1−42.
However, a small population of the K cells also express PC2, lead-
ing to the production of lesser amounts of GIP1−31 and GIP1−31
amide (Cho and Kieffer, 2010). In pancreatic α-cells, proGIP is
processed by both PC3 and PC2 to yield GIP1−31. GLP-1 is pro-
duced by intestinal endocrine L cells throughout the entire small
intestine and colon, with highest levels generated within the dis-
tal ileum and colon (Hansotia and Drucker, 2005). Gcg, the gene
that encodes GLP-1 in the gut, also encodes glucagon in pan-
creatic α-cells. In addition, it encodes GLP-2 in the gut, which
functions as a growth factor for the small intestine (Drucker et al.,
1996). Figure 2A shows the overall structure of the prohormone
and the cleavage sites by PC2 and PC3. In pancreatic α-cells, the
main products generated are glucagon, glicentin-related pancre-
atic polypeptide (GRPP), intervening peptide-1 (IP1) and major
proglucagon fragment (MPGF) (Figure 2B). During embryonic
stages or after pancreatic islets encounter stress, small amounts
of GLP-1 can be detected in pancreatic α-cells (Figure 2B). In
the intestine and brain, the post-translational products include
glicentin, GLP-1, GLP-2, intervening peptide-2 (IP2), GRPP, and
oxyntomodulin (Figure 2B). Figure 2C shows the different GLP-
1 derivatives, as well as the cleavage sites of the GLP-1 degrad-
ing enzymes dipeptidyl peptidase IV (DPP-IV) and NEP 24.11
(Figure 2C). GLP-17−37 and GLP-17−36 amide are the two bio-
logically active forms. GLP-19−36 amide was previously assumed
to be inactive, but was subsequently shown to have protective
effects in the heart (Nikolaidis et al., 2004; Zhao et al., 2006; Ban
et al., 2009; Noyan-Ashraf et al., 2009; Ban et al., 2010; Cho and
Kieffer, 2011). Very recently, the short peptide GLP-128−36 amide
was demonstrated to exhibit beneficial metabolic effects in the
pancreas and liver (Tomas et al., 2011a,b; Liu et al., 2012).
The recognition of the metabolic effects of the incretin hor-
mones led to the creation of the term “enteroinsular axis”, defined
FIGURE 1 | Structure of proGIP and active GIPs. The proGIP, encoded by
the gip gene, is a pro-hormone with 153 amino acid residues. The main
circulating active hormone GIP1−42 (aa 52–81) is generated predominantly in
the intestinal K cells by the pro-hormone convertase PC3. In pancreatic
α-cells and in a small portion of intestinal K cells, the cleavage by both PC2
and PC3 leads to the generation of GIP1−30 (aa 52–93). SS, signal sequence.
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FIGURE 2 | Proglucagon and its cleavage products (proglucagon
derived peptides, PGDPs) including GLP-1. (A) Proglucagon,
encoded by gcg, is a pro-hormone with 160 amino acid residues.
The peptide contains both PC2 and PC3 cleavage sites. (B) A schematic
presentation of the cleavage products in the pancreas (top) and in the
intestine and brain (bottom). Although GLP-1 is not normally produced
in the pancreas, during the embryonic stage or when islets are under
stress, some pancreatic α-cell will produce GLP-1. (C) Amino acid
sequences of GLP-1 and its derivatives, consisting of GLP-17−37
(aa 78–107), GLP-17−36 amide (aa 78–106), GLP-19−36 (aa 80–106), and
GLP-128−36 amide (aa 98–106). GRPP, glycentin related polypeptide;
IP1 and IP2, intervening peptide 1 and 2; MPGF, major proglucagon
fragment; DPP-IV, dipeptidyl peptidase-4; NEP 24.11, neutral
endopeptidase 24.11.
as the connection between the gut and pancreatic islets (Unger
and Eisentraut, 1969). Oral nutrient administration (carbohy-
drate and fat-rich meal) is a potent stimulus of GLP-1 and
GIP secretion. Plasma GIP peaks at 15–30min after oral glu-
cose ingestion (Brown et al., 1975), while a biphasic increase in
plasma GLP-1 can be observed in humans, peaking once at 15–
20min and again at 1–2 h following a meal (Elliott et al., 1993;
Rask et al., 2001). The half-lives of the native incretin hormones
are very short due to the cleavage by DPP-IV, preventing them
from being utilized as therapeutic drugs directly. Two new cat-
egories of T2D drugs, however, have been developed based on
the glucose-lowering effect of GLP-1: GLP-1 analogs such as exe-
natide (or exendin-4) and liraglutide, and inhibitors of DPP-IV
such as sitagliptin and vildagliptin (Wideman and Kieffer, 2009).
Extensive investigations in the past two decades have revealed
both overlapping and contrasting actions of the two incretin
www.frontiersin.org July 2012 | Volume 3 | Article 273 | 3
Chiang et al. Wnt signaling and incretin hormones
hormones. Both GLP-1 and GIP exert their functions mainly
through their respective receptors, both of which belong to
the seven-transmembrane domain G-protein coupled receptor
(GPCR) super-family (Brubaker and Drucker, 2004; Hansotia
and Drucker, 2005). Cyclic AMP (cAMP) and calcium have been
recognized as second messengers for both incretin hormones.
Although initial studies focused on the effects of these two hor-
mones in pancreatic β-cells, GLP-1R and GIPR have been located
on cells in other organs and the extra-pancreatic effects of these
two hormones have been actively investigated.
PANCREATIC FUNCTIONS OF GLP-1 AND GIP
Pancreatic functions of GLP-1 and GIP principally involve the
stimulation of insulin secretion in a synergistic manner with
glucose via the closure of ATP-sensitive K+ channels (KATP),
resulting in subsequent membrane depolarization, rise in intra-
cellular Ca2+ level, and Ca2+-induced insulin secretion (Light
et al., 2002; MacDonald et al., 2002). Both protein kinase A (PKA)
and exchange protein activated by cAMP (Epac) signaling path-
ways were found to be involved in this process (Kwan et al., 2007).
GLP-1 and GIP were also shown to stimulate insulin secretion
via inhibiting voltage-dependent K+ channels (MacDonald et al.,
2002). In addition, GLP-1 as well as GIP increased insulin mRNA
levels, possibly through stimulating insulin gene transcription
and mRNA stability. GLP-1 inhibits glucagon secretion from
α-cells and stimulates the secretion of somatostatin from δ-cells
(D’Alessio et al., 1989; Komatsu et al., 1989). The stimulation
of somatostatin secretion by GLP-1 could be directly mediated
by its receptor on pancreatic islet δ-cells, while the inhibition of
glucagon secretion could be indirectly mediated through the inhi-
bition of somatostatin and the stimulation of insulin secretion.
Additional pancreatic effects of GLP-1 include the sensitization
of β-cells to glucose, as well as the induction of proliferation
and neogenesis of β-cells (Xu et al., 1999; Tourrel et al., 2001; Li
et al., 2003). GLP-1 and exendin-4 (a GLP-1R agonist) were also
shown by our group and others to reduce the expression level of
thioredoxin-interacting protein (TxNIP), a mediator of glucotox-
icity (Chen et al., 2006; Shao et al., 2010). This effect relies on
proteasome-mediated TxNIP degradation, involving both PKA
and Epac signaling cascades (Shao et al., 2010). Thus, in pancre-
atic β-cells, the beneficial effects of GLP-1 consist of its metabolic
effect on stimulating insulin secretion, its proliferative effect on
stimulating β-cell growth and neogenesis, and its protective effect
on reducing glucotoxicity (Yu and Jin, 2010). GIP has not been
shown to reduce β-cell TxNIP level.
EXTRA-PANCREATIC EFFECTS OF GLP-1 AND GIP
GLP-1R is expressed in tissues including pancreatic islet β- and
δ-cells, lung, stomach, heart, intestine, kidney, and certain brain
neurons. Whether it is expressed in hepatocytes is controversial
(Bullock et al., 1996; Ding et al., 2006; Gupta et al., 2010; Pedersen
and Holst, 2011). Figure 3 summarizes pancreatic and extra-
pancreatic functions of GLP-1. It inhibits gastric emptying and
attenuates the postprandial rise in plasma glucose (Wettergren
et al., 1993; Meier et al., 2003). GLP-1 also exhibits cardio-
protective effects in experimental models of cardiac injury (Sokos
et al., 2006; Ban et al., 2008, 2010). In the brain, GLP-1 inhibits
food intake, presumably via the activation of the GLP-1R in the
hypothalamus and brainstem (Turton et al., 1996; Knauf et al.,
2005, 2008; Hayes et al., 2008, 2009). Exending-4 exerts the effect
in hepatocytes, skeletal muscle, and adipocytes in vivo. However,
since GLP-1R expression in those tissues is questionable, these
effects could be due to indirect mechanisms (Baggio andDrucker,
2007). GIPR is expressed in tissues including the pancreas, stom-
ach, small intestine, adipose tissue, heart, testis, endothelial cells,
bone, spleen, thymus, and brain neurons. GIP plays a role in
neural progenitor cell proliferation and behavior modification
(Nyberg et al., 2005). It also stimulates lipogenesis and bone for-
mation (Zhong et al., 2007). Figure 4 summarizes the effects of
GIP. Detailed descriptions of function of these two incretin hor-
mones have been summarized in many excellent review articles
(Brubaker and Drucker, 2004; Estall and Drucker, 2006; Ussher
and Drucker, 2012).
WNT SIGNALING PATHWAY AND TCF7L2
The importance of the Wnt signaling pathway was initially recog-
nized in colon cancer studies and research on embryonic develop-
ment in Drosophila, Xenopus, and other organisms. Wnt ligands,
through their cell membrane bound receptors and co-receptors,
exert many fundamental physiological and pathophysiological
functions in multiple organs and cell lineages, including organo-
genesis, tumorigenesis, and the recently-identified functions in
metabolic homeostasis.
As shown in Figure 5A, the key downstream effector of the
canonical Wnt signaling pathway (defined as Wnt pathway here-
after) is the bipartite transcription factor β-cat/TCF, formed by β-
cat and a member of the TCF family (TCF7, LEF-1, TCF7L1, and
TCF7L2). The level of cytosolic β-cat is tightly controlled by the
proteasome-mediated degradation process, involving the tumor
suppressor adenomatous polyposis coli (APC), axin/conductin,
as well as the serine/threonine kinases glycogen synthase kinase-3
(GSK-3) and casein kinase 1α (CK1α). β-cat is phosphorylated by
GSK-3 and CK1α at Ser33 and several other adjacent serine and
threonine positions to facilitate its degradation. Wnt ligands exert
their regulatory effects via the seven-transmembrane domain friz-
zled receptors and the low-density lipoprotein receptor-related
proteins 5 and 6 (LRP5/6) co-receptors. Following Wnt lig-
and binding, the Wnt receptor associates with disheveled (Dvl)
(Figure 5B). This event triggers the disruption of the com-
plex containing APC, axin, GSK-3, and β-cat, thus preventing
the phosphorylation-dependent degradation of β-cat. In turn,
β-cat enters the nucleus to form the β-cat/TCF complex, result-
ing in the activation of β-cat/TCF (or Wnt) downstream target
genes (Figure 5B). GSK-3 is an important negative modulator
of the Wnt signaling pathway. Lithium and other inhibitors of
GSK-3 have been shown to mimic the function of Wnt lig-
ands in stimulating the expression of Wnt downstream target
genes (Figure 5B). It should be pointed out that extensive recent
studies have revealed that β-cat/TCF also mediates the effect of
signaling cascades other than the Wnt signaling pathway (Jin
et al., 2008). A battery of peptide hormones that utilize cAMP
as their second messenger, insulin, insulin-like growth factor-1
(IGF-1) and other growth factors, as well as the lipid metabo-
lite lysophosphatidic acid (LPA) have been shown to exert their
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FIGURE 3 | Schematic presentation of the function of GLP-1.
In the pancreas, stomach, heart and brain, the effects of GLP-1 are
likely to be mediated by its specific receptor GLP-1R. As GLP-19−37
was also shown to exert protective effects in the heart and improve
cardiac function, whether there is a yet to be identified receptor is
under debate.
effects through the Wnt effector β-cat/TCF (Jin et al., 2008).
Notably, PKA activation leads to β-cat Ser675 phosphorylation,
an event that is positively associated with increased β-cat/TCF
transcriptional activity (Hino et al., 2005; Taurin et al., 2006).
We and others have shown that β-cat Ser675 phosphorylation
can be stimulated by insulin and IGF-1 in gcg-expressing gut
endocrine L cells and in other cell lineages (Sun et al., 2009,
2010), while a very recent study showed that β-cat can be phos-
phorylated by p21-activated protein kinase 1 (Pak1) (Zhu et al.,
2012).
Although TCF7 (TCF-1) was originally isolated as a lymphoid
transcription factor, members of this family are now well rec-
ognized to be transcriptional regulators of many physiological
processes. Shortly after the identification of TCF-1/TCF7, Castrop
et al. isolated cDNAs for TCF7L1 and TCF7L2, which they named
TCF-3 and TCF-4, respectively, (Castrop et al., 1992). Because
the high-mobility group (HMG) boxes of the TCF7L1, TCF7L2,
and TCF7 sequences show striking similarity, Castrop et al. sug-
gested that they represent a subfamily of HMG box-containing
transcription factors (Castrop et al., 1992). Human TCF7L2 gene
was mapped to chromosome 10q25.3 (Duval et al., 2000).
Figure 6 shows the domain structure of TCF7L2. In the
absence of Wnt ligand stimulation, TCF7L2 or other HMG box
TCF proteins function in the nucleus as transcriptional repressors
of Wnt target genes. TCF forms a complex with transcriptional
co-repressors, including Groucho and C-terminal binding pro-
tein 1 (CtBP-1). Both Groucho and CtBP-1 are able to recruit
nuclear co-repressors, such as histone deacetylases (HDACs), to
the promoters of Wnt target genes. β-cat, however, is able to
convert TCF into a transcriptional activator for the same panel
of genes that are repressed by TCF in the absence of β-cat. The
first 41 amino acids of TCF7L2 form the β-cat binding domain.
Deletion of this domain generates a dominant negative molecule
(Yi et al., 2005). A dominant negative form of TCF7L2 was shown
to inhibit the ability of constitutively-active β-cat to stimulate
TCF-dependent transcription (Kolligs et al., 1999). This domi-
nant negative molecule was shown by our group to block both
basal and lithium-stimulated gcg expression in a mouse intestinal
endocrine L cell line (Yi et al., 2005). Very recently, Vacik et al.
demonstrated in the mouse brain the existence of a novel TCF7L2
promoter located upstream of exon 6 (Figure 7). Transcription
from this alternative promoter leads to the generation of a 35 kDa
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FIGURE 4 | Schematic presentation of GIP. Since GIPR has not been detected in hepatic cells, the effect of GIP on reducing gluconeogenesis is likely
due to an indirect mechanism.
TCF7L2 protein, lacking the first 161 amino acid N-terminal
portion, which functions as a native dominant-negative TCF7L2
protein in the brain (Vacik et al., 2011). Whether such a dominant
negative molecule is also expressed in certain peripheral tissues is
currently unknown.
In 1999, Duggirala and colleagues reported that a region on
chromosome 10q was linked to T2D in Mexican Americans
(Duggirala et al., 1999). Reynisdottir et al. had also obtained
evidence for a potential linkage of T2D to 10q in an Icelandic pop-
ulation (Reynisdottir et al., 2003). In 2006, Grant et al. reported
their discovery of the potential linkage between polymorphisms
in TCF7L2 and the risk of T2D (Grant et al., 2006). They geno-
typed 228 microsatellite markers in Icelandic individuals with
T2D and healthy controls across a 10.5Mb interval on chromo-
some 10q. Microsatellite, DG10S478, located within intron 4 of
the TCF7L2 gene, was found to be associated with the risk of
T2D. This observation was then replicated in a Danish cohort
as well as a U.S. cohort (Grant et al., 2006). Two SNPs, namely
rs12255372 and rs7903146, were found to be in strong linkage
disequilibrium with DG10S478 and also showed similar robust
associations with T2D. Heterozygous and homozygous carriers of
the at-risk alleles had relative T2D risks of 1.45 and 2.41, respec-
tively, (Grant et al., 2006). During the past six years, the findings
in this hallmark publication have been repeated in many ethnic
groups by numerous research teams (Cauchi et al., 2006; Florez
et al., 2006; Groves et al., 2006; Chang et al., 2007; Duan et al.,
2007; Florez, 2007, 2008; Lyssenko et al., 2007, 2008; Schafer et al.,
2007; Gonzalez-Sanchez et al., 2008; Ng et al., 2008; Shu et al.,
2008, 2009; Cornelis et al., 2009; da Silva Xavier et al., 2009; Gloyn
et al., 2009; Pilgaard et al., 2009; Alibegovic et al., 2010; Groop,
2010; Dabelea et al., 2011; Gjesing et al., 2011). As shown in
Figure 7, the T2D risk TCF7L2 SNPs are mainly localized within
the two large intronic regions surrounding exon 5. Although it
will be challenging to determine how these SNPs affect the risk
of T2D, several studies suggest that these SNPs affect the incretin
effect of pancreatic β-cells and hepatic gluconeogenesis (Lyssenko
et al., 2007, 2008; Shu et al., 2008, 2009). Since there are a num-
ber of alternatively spliced TCF7L2 isoforms, it has been suggested
that the risk SNPs affect the expression as well as the alternative
splicing of TCF7L2.
WNT PATHWAY CONTROLS INCRETIN GENE
EXPRESSION
We have demonstrated previously that both lithium (which mim-
ics the function of Wnt ligands) and a constitutively-active β-cat
(S33Y mutant) stimulated the activity of the gcg promoter (Ni
et al., 2003). Lithium was also shown to stimulate endogenous gcg
mRNA expression and GLP-1 production in the mouse intestinal
GLUTag and STC-1 cell lines, as well as in fetal rat intestinal cell
(FRIC) cultures (Ni et al., 2003). We then identified that the stim-
ulatory effect of lithium on gcg expression occurred in intestinal
endocrine L cells, but not in pancreatic α-cells. Activation of gcg
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FIGURE 5 | A simplified illustration of the canonical Wnt signaling
pathway. (A) In the absence of Wnt ligand stimulation, β-cat is located within
the “destruction complex”, phosphorylated by GSK-3 and CK-1α at Ser33 and
adjacent serine positions, which leads to proteasome-mediated degradation
process. (B) Following Wnt ligand stimulation, the destruction complex
disassembles, resulting in free β-cat accumulation. It then enters the
nucleus and forms the bipartite transcription factor β-cat/TCF, which
leads to the stimulation of Wnt target gene expression. Lithium is an
inhibitor of GSK-3, while cAMP signaling and insulin are able to stimulate
β-cat Ser675 phosphorylation. Thus, in certain cell lineages, β-cat/TCF can
also mediate the effect of lithium, cAMP, and insulin on Wnt target gene
expression.
FIGURE 6 | Structure and functional domains of human TCF7L2. It is currently unclear which position of the domains that interact with Groucho and CtBP1.
Smad4 is the major mediator of the TGFβ signaling cascade. HBP1, HMG-box transcription factor 1, a transcriptional repressor.
promoter activity is dependent upon a TCF binding site within
the G2 enhancer element of the gcg promoter (Yi et al., 2005).
Since the G2 enhancer element has been shown by Furstenau
et al. to mediate the stimulatory effects of both cAMP and cal-
cium on gcg promoter activity (Furstenau et al., 1999), this
observation raised the question as to whether cAMP activates
gcg expression via cross-talking with the Wnt signaling pathway.
Using chromatin immunoprecipitation (ChIP), we then demon-
strated an in vivo physical interaction between TCF7L2 and the
G2 enhancer element (Yi et al., 2005). Western blotting, RT-PCR,
and immunostaining demonstrated that TCF7L2 is abundantly
expressed in intestinal GLP-1 producing cells (Yi et al., 2005).
Furthermore, dominant-negative TCF7L2 attenuated both basal
and lithium-stimulated gcg mRNA expression in the intestinal
endocrine L cell line GLUTag (Yi et al., 2005). Interestingly, gip
mRNA expression was also shown to be stimulated by the Wnt
signaling cascade (Garcia-Martinez et al., 2009). García-Martínez
and colleagues demonstrated that lithium or Wnt/β-cat signaling
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FIGURE 7 | Depiction of the position of seven T2D risk SNPs
in the human TCF7L2 gene. Human TCF7L2 is located on
chromosome 10q25.3. The two SNPs that have been more
extensively studied are shown in red. Ex1b-e indicates the
relative position of a novel promoter, which is active in neuronal
cells during embryonic stages and leads to the generation of
dominant negative TCF7L2, lacking the first 161 amino acid residues
at the N terminus.
enhances GIP production by entero-endocrine cells through a
conserved TCF binding site within the proximal region of the
gip promoter. In contrast to the positive effect of TCF7L2 on
gcg promoter transcription, ChIP analysis showed that lithium
treatment led to a favorable binding of the bipartite transcription
factor of β-cat/LEF-1 to the gip promoter, reducing the bind-
ing of TCF7L2 and the nuclear co-repressor histone deacetylase
1 (HDAC1) (Garcia-Martinez et al., 2009). Thus, although Wnt
signaling positively regulates the expression of both GIP and
GLP-1, they are differentially regulated by the effectors LEF-1 and
TCF7L2, respectively, (Garcia-Martinez et al., 2009).
POTENTIAL EFFECT OF WNT EFFECTORS β-CAT
AND TCF7L2 IN PANCREATIC β-CELLS
To explore the mechanistic role of TCF7L2 SNPs in conferring the
risk of T2D, Schafer et al genotyped 1100 non-diabetic German
participants for the five known TCF7L2 SNPs and conducted oral
glucose tolerance tests on these subjects (Schafer et al., 2007).
They then measured GLP-1 secretion and performed intravenous
glucose tolerance tests in a portion of the participants. Their
results confirmed that TCF7L2 SNPs are associated with reduced
insulin secretion. Plasma GLP-1 concentrations during oral glu-
cose tolerance tests, however, were not correlated with the status
of TCF7L2 SNPs. These observations indicate that TCF7L2 poly-
morphisms may mainly affect the incretin response rather than
the production of the incretin hormone. Many investigators have
thus focused on assessing the function of TCF7L2 in pancreatic
β-cells (Shu et al., 2008, 2009; Liu and Habener, 2008).
A series of studies by Maedler’s group revealed the ben-
eficial effects of TCF7L2 in pancreatic β-cells (Shu et al.,
2008, 2009). They found that in isolated human islets,
siRNA-mediated TCF7L2 depletion resulted in increased β-cell
apoptosis, decreased β-cell proliferation, and decreased glucose-
stimulated insulin secretion. Similar effects were seen following
TCF7L2 depletion in mouse islets. In contrast, TCF7L2 over-
expression protected islets from glucose- and cytokine-mediated
apoptosis of pancreatic β-cells. They concluded that TCF7L2
plays a beneficial role on both β-cell function and survival. They
then investigated the correlation between the pancreatic level of
TCF7L2 and the levels of GLP-1R and GIPR. In the diabetic
db/db mouse model, the Vancouver Diabetic Fatty (VDF) Zucker
rat and the high fat/high sucrose diet-treated mouse model,
TCF7L2 protein levels were lower in the diabetic animals despite
an increase in TCF7L2 mRNA levels in isolated islets compared
to control animal islets. A similar trend was also observed in pan-
creatic sections from patients with T2D. In parallel, expression of
GLP-1R and GIPR was also lower in islets from humans with T2D
as well as in isolated human islets treated with TCF7L2 siRNA.
Also, glucose-, GLP-1-, and GIP-stimulated insulin secretion, but
not KCl- or cAMP-stimulated insulin secretion, was impaired in
TCF7L2 siRNA-treated isolated human islets. Loss of TCF7L2
resulted in decreased GLP-1- and GIP-stimulated AKT phospho-
rylation, and AKT-mediated Foxo-1 phosphorylation and nuclear
exclusion. These findings suggest that β-cell function and survival
are positively regulated through the interplay between TCF7L2
and GLP-1R/GIPR expression and signaling in T2D. These obser-
vations, however, are in contrast with the potential deleterious
effect of TCF7L2 in pancreatic β-cells. For example, Lyssenko
et al. reported that the CT/TT genotypes of SNP rs7903146 are
strongly associated with the risk of T2D in two independent
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cohorts. This risk T allele was associated with impairments in
insulin secretion, incretin effects, and enhanced rate of hepatic
glucose production (Lyssenko et al., 2007). Furthermore, the car-
riers of the TT alleles exhibited increased pancreatic TCF7L2
mRNA level. Although TCF7L2 expression was positively corre-
lated with insulin gene expression, it correlated inversely with
glucose-stimulated insulin release (Lyssenko et al., 2007). Based
on these observations, we would speculate that the TCF7L2 risk
allele is associated with increased TCF7L2 expression, and this
is deleterious to the incretin effect and glucose disposal. More
recently a transgenic mouse study has also demonstrated the
deleterious effect of TCF7L2 in pancreatic islets (Savic et al.,
2011). Briefly, TCF7L2 null mice display enhanced glucose tol-
erance coupled with significantly lowered insulin levels, while
TCF7L2 over-expression displayed reciprocal phenotypes (Savic
et al., 2011). Great efforts have been made to determine the
alternative splicing of TCF7L2 (Osmark et al., 2009; Prokunina-
Olsson et al., 2009; Prokunina-Olsson and Hall, 2010; Locke et al.,
2011; Savic et al., 2011). It is unclear but possible that different
isoforms of TCF7L2 may exert different or even opposite func-
tions (Le Bacquer et al., 2011), which may explain the seemingly
controversial conclusions made by different groups on the ben-
eficial versus deleterious role of TCF7L2 in β-cells, as discussed
above (Lyssenko et al., 2007; Shu et al., 2008, 2009; da Silva Xavier
et al., 2009; Savic et al., 2011).
Liu and Habener assessed the involvement of TCF7L2 and
β-cat in glucose disposal from another angle (Liu and Habener,
2008). They assessed the expression of TCF7L2 in the rat pan-
creatic β-cell line Ins-1 and determined the presence of Wnt
activity in pancreatic islets using the TOPGAL transgenic mice.
In this mouse model, the expression of the β-galactosidase (LacZ)
reporter is under the control of a regulatory sequence consisting
of three consensus LEF/TCF binding sites upstream of a mini-
mal c-fos gene promoter (DasGupta and Fuchs, 1999). Liu and
Habener found that islets from TOPGAL mice show increased
LacZ expression in response to exendin-4 treatment, although
basal LacZ expression in islets was shown to be low (Liu and
Habener, 2008). This observation suggests that β-cat/TCF, the
effector of the Wnt signaling, mediates the effect of GLP-1 in
stimulating β-cell proliferation. The positive pancreatic LacZ
staining in the TOPGAL mice, however, could not be repeated by
other investigators (Columbus et al., 2010; Krutzfeldt and Stoffel,
2010).
METABOLIC FUNCTION OF TCF7L2 IN ORGANS OTHER
THAN THE PANCREAS AND GUT
TCF7L2 is also expressed in organs other than pancreatic islets,
such as liver, brain, muscle, and fat tissues, which are also impor-
tant for metabolic homeostasis. Although the Wnt signaling
pathway is known to be important in the development and zona-
tion of the embryonic liver (Gebhardt and Hovhannisyan, 2010),
little effort has been made to explore the hepatic role of TCF7L2
and Wnt signaling in regulating glucose homeostasis in adult-
hood. Liu et al. reported that starvation induced the expression
of mRNAs encoding different Wnt isoforms in hepatocytes. They
also demonstrated with gain- and loss-of-function models that
β-cat mediates hepatic glucose production (Liu et al., 2011).
Briefly, β-cat ablation improved glucose disposal and inhibited
the expression of gluconeogenic gene expression, while β-cat
over-expression showed the reciprocal effect (Liu et al., 2011).
This group, however, did not directly assess the contribution of
TCF7L2. Norton et al. demonstrated that TCF7L2 silencing led to
increased basal levels of hepatic glucose production in a rat hep-
atic cell line, associated with the over-expression of gluconeogenic
genes including those encodes phosphoenolpyruvate carboxyki-
nase (pepck) and glucose-6-phosphatase (g6pase) (Norton et al.,
2011). Using ChIP combined with massive parallel DNA sequenc-
ing (ChIP-Seq), they detected more than 2000 binding events
across the genome (Norton et al., 2011). They suggested that
TCF7L2 may affect fasting and postprandial hyperglycemia in
carriers of T2D risk SNPs of TCF7L2 (Norton et al., 2011).
Wnt signaling and TCF7L2 negatively regulate adipogen-
esis (Ross et al., 2000) but positively regulate bone forma-
tion (Manolagas and Almeida, 2007). Wnt ligands released by
adipocytes stimulate insulin secretion (Schinner et al., 2008).
TCF7L2 is expressed in adipocytes and its expression can be
down-regulated by insulin (Ahlzen et al., 2008). In cultured
adipocytes, insulin repressed TCF7L2 expression, and the repres-
sion can be attenuated by free fatty acids palmitate or oleate
(Ahlzen et al., 2008). In insulin-resistant human subjects, sub-
cutaneous adipose tissue (SAT) expresses higher levels of TCF7L2
(Ahlzen et al., 2008). Prokunina-Olsson and colleagues found that
omental and SAT express different alternatively spliced forms of
TCF7L2. However, there is no association between the expression
of alternatively spliced TCF7L2 isoforms and TCF7L2 T2D risk
SNPs (Prokunina-Olsson et al., 2009).
SUMMARY AND PERSPECTIVE
A fundamentally important advancement in the basic research of
the Wnt signaling pathway is that the bipartite transcription fac-
tor β-cat/TCF mediates not only the effect of Wnt signaling, but
also other signaling pathways, including peptide hormones that
utilize cAMP as a second messenger (Jin et al., 2008). This, along
with the breakthrough discovery that TCF7L2 is a T2D risk gene
through GWAS (Grant et al., 2006), facilitated the investigation
of the role of Wnt signaling pathway in metabolic homeostasis.
Investigations made during the past few years have shown that
the production of GLP-1 and GIP is positively regulated by the
effectors of the Wnt signaling pathway (Yi et al., 2005; Garcia-
Martinez et al., 2009). Furthermore, β-cat/TCF7L2 mediates the
function of GLP-1 in stimulating β-cell proliferation (Liu and
Habener, 2008), and that TCF7L2 plays a role in up-regulating
the expression of GLP-1R and GIPR (Shu et al., 2009).
Although it is clear that TCF7L2 polymorphisms are strongly
associated with the risk of T2D in multiple ethnic groups, the
mechanism underlying this association is far from complete at
this time. Since no risk SNPs of T2D have been identified within
TCF7L2 coding region, or a region that can be reliably determined
to have a strong effect on TCF7L2 expression or alternative splic-
ing, we still cannot rule out the possibility that the risk SNPs of
TCF7L2 affect T2D susceptibility via a mechanism that does not
involve TCF7L2 itself, but rather that the SNPs are evolutionarily
linked to the inheritance of a genetic defect elsewhere (Jin and Liu,
2008). In the future, we anticipate more thorough investigation
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on the association between TCF7L2 SNPs and the alternative
splicing of TCF7L2 in pancreatic islets and other organs. Great
insights could also be gained through further studies on the ben-
eficial versus deleterious effects of TCF7L2 alternatively spliced
variants in different organs.
Both TCF7L2 expression and Wnt activity have been clearly
demonstrated in adult organs including liver, adipocytes, and
brain. These organs are important in regulating glucose and
energy homeostasis, as well as eating behavior. In the liver,
TCF7L2 is likely to act as negative mediators of gluconeoge-
nesis (Norton et al., 2011). However, β-cat ablation has been
shown to improve glucose disposal and inhibit gluconeogenic
gene expression (Liu et al., 2011). This is likely due to the fact
that the FOXO signaling pathway is also importantly involved
in hepatic gluconeogenesis and that FOXO cross-talks with the
Wnt signaling pathway (Manolagas and Almeida, 2007; Jin et al.,
2008; Norton et al., 2011). An evolutionarily conserved inter-
action between β-cat and FOXO proteins was demonstrated by
Essers et al. in 2005 (Essers et al., 2005). We hence learned that
FOXO and TCF compete for their common co-factor β-cat in
order to exert their physiological or pathophysiological functions
(Jin et al., 2008). FOXO mediates the effect of glucagon signaling
in stimulating the transcription of gluconeogenic genes includ-
ing pepck during hypoglycemia, which is turned off by insulin
during hyperglycemia by insulin. The attenuation of the expres-
sion of pepck and other gluconeogenic genes by knocking down
β-cat suggests that FOXO requires β-cat to stimulate pepck tran-
scription (Liu et al., 2011). How does one explain the contrasting
observation that both Wnt signaling and another effector of Wnt
signaling pathway, TCF7L2, negatively regulate gluconeogenic
gene expression (Norton et al., 2011)? One may speculate that
β-cat is a limiting factor for the FOXO signaling cascade in up-
regulating gluconeogenic gene expression during fasting, while
the repression of gluconeogenic gene expression by Wnt acti-
vation or TCF7L2 over-expression does not rely on β-cat as a
limiting factor after feeding. Alternatively, TCF7L2 may utilize
a yet to be explored mechanism or co-factor to repress gluco-
neogenic gene expression. These potential mechanisms deserve
further investigation.
Adipocytes also express TCF7L2. In human adipocytes,
TCF7L2 expression can be down-regulated by insulin (Ahlzen
et al., 2008), in contrast to the stimulatory effect of insulin on
TCF7L2 expression in pancreas and gut (Columbus et al., 2010;
Sun et al., 2010). Insulin is a potent inducer of adipogenesis,
while Wnt signaling is known to inhibit adipogenesis (Ross et al.,
2000; Ahlzen et al., 2008; Schinner, 2009). Down-regulation of
TCF7L2 by insulin in adipocytes may hence mediate the stim-
ulation of adipogenesis by insulin. This raises the question as
to whether known adipogenic genes are negatively regulated by
TCF7L2. If they are, what is the co-factor for TCF7L2 in medi-
ating its repressive effect? This line of research will broaden our
knowledge on adipogenesis and provide potential novel targets
for controlling obesity. Insulin is known to repress pancreatic gcg
expression (Philippe, 1991), in contrast to its stimulatory effect on
gcg expression in the gut (Yi et al., 2008). Since insulin has been
shown to exert opposite effects on the expression of TCF7L2 in
different tissues, to explore mechanistically how insulin represses
TCF7L2 in adipocytes will also broaden our basic knowledge on
the role of insulin in regulating gene expression.
Both GLP-1 and GIP are expressed in the brain. We have
learned that brain GLP-1 signaling controls satiety (Turton et al.,
1996; Baggio and Drucker, 2007), while exogenous GIP admin-
istration in the rat induces proliferation of hippocampal pro-
genitor cells (Nyberg et al., 2005). Wnt signaling pathway is
evidently involved in neuron cell differentiation and survival.
TCF7L2 is expressed in different brain neuronal cell types,
and TCF7L2 knockout mice carry abnormalities in their pitu-
itary gland (Brinkmeier et al., 2007). Since TCF7L2 or Wnt
signaling pathway play an important role in the expression
of peripheral GLP-1 and GIP (Yi et al., 2005, 2008; Garcia-
Martinez et al., 2009), it is necessary to examine whether TCF7L2
and Wnt signaling control brain incretin hormone production
and function.
In summary, the studies on the expression and function of
incretin hormones has enriched our understanding of the mecha-
nisms underlying glucose and energy homeostasis, and have led to
the development of two novel categories of therapeutic drugs for
T2D and its complications. The recognition of the involvement
of Wnt signaling in metabolic homeostasis and the association
between TCF7L2 polymorphisms and the risk of T2D further
prompted us to explore the role of Wnt signaling and TCF7L2 in
the production and function of the incretin hormones. Although
majority of the studies have been conducted in pancreatic β-cells,
we will likely see more extensive investigations on the role of Wnt
signaling and its effectors in organs other than pancreatic islets
and potentially the identification of novel therapeutic targets for
T2D and other metabolic disorders.
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